Purchase Order 75N91024P00557

Award Date 9/26/24
Potential Completion Date 9/25/27
Potential Value $946K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Germantown, MD, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $467,900 firm fixed price purchase order was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Qiagen, LLC. The contract calls for Qiagen to provide clinical interpretation services for genomic variants identified through large next-generation gene panels, whole exome sequencing, and whole transcriptome sequencing conducted as part of NCI's Clinical Oncologic Molecular Pathology...
Qiagen, LLC was awarded a firm fixed price purchase order valued at approximately $723,300 by the National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services. Under this contract, Qiagen will provide clinical interpretation of genomic variants from large next-generation panel testing, whole exome sequencing, and whole transcriptome sequencing. Performance will take place in Germantown, Maryland over a two year period concluding...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency of the Department of Health and Human Services (HHS), to Qiagen, LLC, a division of the international biotechnology company Qiagen N.V. The $24,632.58 fixed-price contract with economic price adjustment is for a blanket purchase agreement (BPA) call order, with an ultimate completion date of July 3, 2018. Qiagen, which has provided products and services to support federal agencies' biomedical...
This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Qiagen, LLC, a division of the international biotechnology company Qiagen N.V. The contract, valued at $15,641.00, is for the provision of genomic research and analysis tools, including DNA/RNA extraction kits, next-generation sequencing, digital PCR systems, sample preparation equipment, and bioinformatics software....
This federal contract award was made by the National Institutes of Health (NIH) Clinical Center to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics, scientific equipment, and bioinformatics solutions. The $12,332.71 firm fixed-price purchase order is for the delivery of Qiagen's products and services, which likely include DNA/RNA extraction kits, next-generation sequencing equipment, digital PCR systems, sample preparation instruments, precision medicine analysis...
This federal contract award was made by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Qiagen, LLC, a division of the international provider Qiagen N.V. The $4,060.08 firm fixed price contract is a Blanket Purchase Agreement (BPA) call order for the delivery of various products and services to support the NCI's biomedical research, public health, and healthcare programs. Based on Qiagen's capabilities, the contract likely involves the...
This is a $10,768 firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Qiagen, LLC, a division of the international biotechnology company Qiagen N.V. The contract is for the provision of Qiagen's clinical insight analysis products and services, with a period of performance through September 28, 2026. Qiagen, a foreign-owned, for-profit manufacturer, specializes in molecular diagnostics, scientific equipment, and bioinformatics solutions. The...
This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Qiagen, LLC, a division of the international biotechnology company Qiagen N.V. The $22,324.00 contract is for the provision of various products and services to support the NIH's biomedical research, public health, and healthcare programs, including DNA/RNA extraction kits, next-generation sequencing, digital PCR systems,...
This federal contract award was issued by the National Institutes of Health (NIH) Clinical Center to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics, scientific equipment, and bioinformatics solutions. The $11,343.80 firm fixed-price purchase order is for QIASEQ TARGETED DNA CUSTOM PANEL (96) - 6601-6700, CDHS-47388Z-6699 products. The contract has an ultimate completion date of September 27, 2025. Qiagen, LLC is a division of the international biotechnology...
This is a firm fixed-price purchase order contract awarded by the National Institute of Environmental Health Sciences (NIEHS) to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics and genomic analysis products. The $389,994.64 contract, which does not have a set-aside designation, is for the delivery of various scientific equipment and consumables to support NIEHS's biomedical research and public health initiatives. Key items included under the contract are DNA/RNA...

This is a federal contract award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics and bioinformatics solutions. The $945,938 firm-fixed-price contract is for the "Evidence-Based Bioinformatic Interpretation of New Generation Sequencing Data for Precision Cancer Diagnostics."

The contract was awarded on a sole-source basis under FAR Part 12 for commercial items, with no set-aside designation. Qiagen will provide access to its QIAGEN Clinical Insight Interpret (QCII) bioinformatics analysis platform to support the NCI-COMPASS program's next-generation sequencing data analysis and clinical reporting for cancer patient care. The contract has a 12-month base period with two 12-month option periods. Qiagen holds several significant federal Indefinite Delivery Vehicles (IDVs) across multiple agencies, demonstrating its role as a critical supplier of advanced scientific technologies to government research, healthcare, and law enforcement agencies.

Generated 9/27/25, 9:52 AM